Shionogi & Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Isao Teshirogi
- Full Time Employees
- 6,223
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Park Tower Osaka OS Japan 530-0011
- IPO Date
- May 16, 1949
- Website
- shionogi.co.jp
- Similar Companies
- Business
- Shionogi & Co., Ltd. is a research-driven Japanese pharmaceutical company dedicated to the discovery, development, production, and worldwide distribution of innovative medicines, diagnostic solutions, and medical devices. The company cultivates a strong global presence, with operations spanning Japan, North America, and Europe. The firm's portfolio features key treatments such as Fetroja (cefiderocol) for managing multidrug-resistant Gram-negative bacterial infections and Xofluza, an antiviral medication for influenza, which recently saw a new granule formulation launch. Additionally, Shionogi holds a significant equity stake in ViiV Healthcare, contributing to vital therapies for HIV, including the development of integrase inhibitors. Other marketed products include Symproic (naldemedine tosilate) for opioid-induced constipation. Shionogi maintains a robust development pipeline, primarily concentrated on areas of high unmet medical need like infectious diseases, central nervous system disorders, and pain. Promising candidates in clinical stages include a COVID-19 preventive vaccine (Covgoze), an oral antiviral treatment for COVID-19 (Ensitrelvir Fumaric Acid, also known as Xocova in Japan), and an investigational long-acting formulation for COVID-19 pre-exposure prophylaxis. The company is also advancing Zuranolone for depression, in collaboration with Sage Therapeutics, with a new drug application submitted in Japan. In the realm of quality of life diseases, the digital therapeutic app ENDEAVORRIDE® (SDT-001) for pediatric Attention-Deficit/Hyperactivity Disorder received domestic marketing approval in Japan. Other pipeline projects target conditions such as Fragile X syndrome and Alzheimer's disease (BPN14770), decompensated liver cirrhosis (ADR-001), acute ischemic stroke (Redasemtide Trifluoroacetate), and various solid tumors (S-531011). The pipeline further includes novel antibiotics like S-743229 for complicated urinary tract infections and S-649228 for Gram-negative infections, stemming from the acquisition of Qpex Biopharma, Inc. Recent strategic initiatives include the acquisition of Torii Pharmaceutical and Akros Pharma in May 2025 to bolster domestic commercial reach and enhance global development capabilities, particularly in areas like dermatology and pediatrics. Furthermore, Shionogi announced a planned merger with its wholly-owned subsidiary, Shionogi Pharma Co., Ltd., set for April 2027, to fortify its production and supply chain resilience. Established in 1878, Shionogi & Co., Ltd. is headquartered in Osaka, Japan.
Company News
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Jumps 6.2% on Analyst Upgrade
Shionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should Know
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Financial Analysis: Orion OYJ (OTCMKTS:ORINY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened
Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Shares Down 7.1% – Here’s What Happened
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
Shionogi Announces U.S. Government Procurement of Fetroja® (cefiderocol) Through BARDA's Project BioShield to Support National Preparedness for Drug-Resistant Bacterial Threats
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
SGIOY vs. SDZNY: Which Stock Is the Better Value Option?
Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease
SGIOY vs. SDZNY: Which Stock Should Value Investors Buy Now?
SGIOY or SDZNY: Which Is the Better Value Stock Right Now?
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Hits New 12-Month High – Should You Buy?
Analyzing Zoetis (NYSE:ZTS) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)